Annual Securities Report — FY2025
What Renascience Inc. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-23View the original on EDINET
How much it says
61Detailed
What moved here
45named for the first time
Its own wording
76terms
Which filing this is
15/ 15newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The Company is advancing research and development centered on pharmaceuticals such as RS5614 and medical devices and AI, including SaMD. The filing reports publication of the XPRIZE Healthspan semifinal trial results and the continuation and launch of clinical trials for each pipeline. It also reflects the issuance of new shares and share acquisition rights through the third and fourth private placements as fundraising for the fiscal year ended March 2026, along with the results and cash flows for the fiscal year.
Komori's summary of this document, not the document's own words.61Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
61
Detailed
40
Thin
50
Typical
50
Typical
68
Detailed
55
Typical
100
Very detailed
60
Detailed
55
Typical
50
Typical
R&D spend2億円Money spent making new things.
Cash left overNot disclosedThis document does not carry the figure.
Spent on equipmentNot disclosedThis document does not carry the figure.
Employees3Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.